Results 181 to 190 of about 155,595 (295)
Korea in Global Value Chains: Pathways for Industrial Transformation
The Korea Institute for Industrial Economics & Trade (KIET) commissioned a global value chain study to Duke University Global Value Chains Center (Duke GVCC).
Frederick, Stacey +5 more
core
Industrial robots reduce carbon emissions in manufacturing through global value chains. [PDF]
Zhang Y, Zhu J, Wang S.
europepmc +1 more source
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket +14 more
wiley +1 more source
Industry-level estimates of export quality accounting for global value chains. [PDF]
Wacker KM, Ye X, Tusha D, Celani A.
europepmc +1 more source
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi +5 more
wiley +1 more source
A value chain and cluster perspective on competitiveness of European fresh vegetable production – Case studies from Germany, Italy, and Spain [PDF]
In the present study we combine cluster theory with a value chain approach, with the aim of discovering elements of the European fresh vegetable business that could enable local producers to gain competitive advantages in a global market.
Bettina Riedel
core
Negotiating the ethical terrain in global value chains on the road towards the SDGs. [PDF]
Sinkovics N +3 more
europepmc +1 more source
Demand and supply exposure through global value chains: Euro-Mediterranean countries during COVID. [PDF]
Ayadi R +4 more
europepmc +1 more source
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw +5 more
wiley +1 more source

